Notably, we observed that MKP1 expression is regulated by epigenetic modifications in glioma cells and, HDACIs are a group of epigenetic molecules with promising results in pre-clinical and clinical trials in gliomas and in particular with glioblastomas27, 48, and some (SAHA, romidepsin and bellinostat) have received approval from the FDA for the treatment of cutaneous T-cell lymphoma. This evidence concerns the gene DUSP1 and primary cutaneous T-cell non-Hodgkin lymphoma.